Literature DB >> 10067984

Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.

S L Merbs1, D Sidransky.   

Abstract

PURPOSE: To define more clearly the role of the tumor suppressor gene p16 in uveal melanoma by determining the relative contribution of all known mechanisms of p16 inactivation in this tumor.
METHODS: A comprehensive genetic analysis of the p16 gene was performed in 33 primary sporadic ciliochoroidal and choroidal melanomas. Fourteen highly polymorphic microsatellite markers surrounding the p16 locus on chromosome 9p21 were used for the microsatellite analysis. Sequence analysis of the p16 gene was performed on those tumors with 9p21 loss of heterozygosity. To investigate methylation as an alternative mechanism of inactivation of p16, methylation-specific polymerase chain reaction was performed on all tumor DNA samples.
RESULTS: Loss of heterozygosity (LOH) was found in 8 of 33 (24%) uveal melanomas. No evidence of a second region of LOH that did not include the p16 locus was found. Four cases had hemizygous losses including markers both distal and proximal to p16. Homozygous deletion of the p16 gene was detected in the 4 remaining cases by microsatellite analysis. Sequence analysis revealed no p16 mutations in the tumors with hemizygous loss of p16. Methylation of the 5' CpG island of p16 was found in one tumor with 9p21 LOH and in another without LOH.
CONCLUSIONS: p16 inactivation by HD or methylation occurs in 27% of uveal melanomas, representing the most common molecular genetic alteration identified thus far in uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067984

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.

Authors:  Manju L Prasad; Snehal G Patel; Jatin P Shah; Stacy Hoshaw-Woodard; Klaus J Busam
Journal:  Head Neck Pathol       Date:  2011-12-13

Review 2.  Focus on molecules: 5-methylcytosine, a possible epigenetic link between ageing and ocular disease.

Authors:  Kenneth P Mitton; Alvaro E Guzman
Journal:  Exp Eye Res       Date:  2010-07-08       Impact factor: 3.467

Review 3.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Deregulation of the Rb and p53 pathways in uveal melanoma.

Authors:  M A Brantley; J W Harbour
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.

Authors:  B Buecher; M Gauthier-Villars; L Desjardins; L Lumbroso-Le Rouic; C Levy; A De Pauw; J Bombled; C Tirapo; C Houdayer; B Bressac-de Paillerets; D Stoppa-Lyonnet
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

6.  Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

Authors:  M A Brantley; J W Harbour
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

Review 7.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

8.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

Review 9.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

Review 10.  Genetic determinants of uveal melanoma.

Authors:  Jasbir Kaur; Manzoor Ahmad Malik; Rishabh Gulati; Shorya Vardhan Azad; Sandeep Goswami
Journal:  Tumour Biol       Date:  2014-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.